Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs State Street SPDR S&P Biotech ETF — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.75 (market cap $2.98B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.4× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| FNGU | XBI | |
|---|---|---|
Market Cap | $2.98B | $10.11B |
Volume | 4,682,352 | 12,903,266 |
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $37.20 | $169.55 |
52-Week Low | $13.73 | $104.99 |
Typical Hold Time | 19 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.62, down 1.56% today. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. The ETN provides triple exposure to tech giants like Nvidia, Meta, and Apple, but carries significant volatility risks as highlighted by recent analysis showing an 87% decline during previous tech sector downturns.
The outlook remains highly speculative given the leveraged structure. While bullish technicals suggest potential upside if tech stocks continue performing, the extreme volatility and historical drawdowns present substantial risk. Investors should weigh the amplified returns against the possibility of rapid losses during market corrections.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
